Log in

PDS Biotechnology Stock Forecast, Price & News

+0.16 (+8.16 %)
(As of 11/27/2020 12:00 AM ET)
Today's Range
Now: $2.12
50-Day Range
MA: $2.16
52-Week Range
Now: $2.12
Volume433,653 shs
Average Volume862,416 shs
Market Capitalization$47.20 million
P/E RatioN/A
Dividend YieldN/A
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial, a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104 (TRP2) for the treatment of melanoma. The company has a collaboration agreement with Merck & Co. to combine PDS0101 with Keytruda, a checkpoint inhibitor to treat human papillomavirus positive recurrent or metastatic head and neck cancer; and an agreement with Farmacore Biotechnology for the development of Versamune-based vaccine to prevent COVID-19 infection. The company is based in Princeton, New Jersey.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.59 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:PDSB



Sales & Book Value

Annual SalesN/A
Book Value$2.22 per share


Net Income$-7,000,000.00


Market Cap$47.20 million
Next Earnings Date3/26/2021 (Estimated)
OptionableNot Optionable
+0.16 (+8.16 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PDSB News and Ratings via Email

Sign-up to receive the latest news and ratings for PDSB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

PDS Biotechnology (NASDAQ:PDSB) Frequently Asked Questions

How has PDS Biotechnology's stock price been impacted by COVID-19 (Coronavirus)?

PDS Biotechnology's stock was trading at $0.9201 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PDSB shares have increased by 130.4% and is now trading at $2.12.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of PDS Biotechnology?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PDS Biotechnology in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for PDS Biotechnology
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than PDS Biotechnology?

Wall Street analysts have given PDS Biotechnology a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but PDS Biotechnology wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is PDS Biotechnology's next earnings date?

PDS Biotechnology is scheduled to release its next quarterly earnings announcement on Friday, March 26th 2021.
View our earnings forecast for PDS Biotechnology

How were PDS Biotechnology's earnings last quarter?

PDS Biotechnology Co. (NASDAQ:PDSB) issued its earnings results on Monday, November, 16th. The company reported ($0.23) EPS for the quarter, missing the Zacks' consensus estimate of ($0.14) by $0.09.
View PDS Biotechnology's earnings history

What price target have analysts set for PDSB?

4 brokerages have issued twelve-month price targets for PDS Biotechnology's shares. Their forecasts range from $6.00 to $10.00. On average, they anticipate PDS Biotechnology's share price to reach $7.28 in the next year. This suggests a possible upside of 243.2% from the stock's current price.
View analysts' price targets for PDS Biotechnology

Are investors shorting PDS Biotechnology?

PDS Biotechnology saw a increase in short interest in October. As of October 30th, there was short interest totaling 351,300 shares, an increase of 66.8% from the October 15th total of 210,600 shares. Based on an average trading volume of 550,200 shares, the short-interest ratio is currently 0.6 days.
View PDS Biotechnology's Short Interest

Who are some of PDS Biotechnology's key competitors?

What other stocks do shareholders of PDS Biotechnology own?

Who are PDS Biotechnology's key executives?

PDS Biotechnology's management team includes the following people:
  • Dr. Frank K. Bedu-Addo, Pres, CEO & Director (Age 56, Pay $751.25k)
  • Dr. Gregory L. Conn, Chief Scientific Officer (Age 65, Pay $251.84k)
  • Mr. Michael N. King, Interim CFO & Principal Accounting Officer
  • Deanne Randolph, Investor Relations Officer
  • Ms. Lauren V. Wood M.D., Chief Medical Officer (Age 60)
  • Ms. Janetta Trochimiuk, Controller (Age 57)

What is PDS Biotechnology's stock symbol?

PDS Biotechnology trades on the NASDAQ under the ticker symbol "PDSB."

Who are PDS Biotechnology's major shareholders?

PDS Biotechnology's stock is owned by a number of retail and institutional investors. Top institutional investors include Inspirion Wealth Advisors LLC (1.55%) and BlackRock Inc. (0.68%).

Which institutional investors are buying PDS Biotechnology stock?

PDSB stock was purchased by a variety of institutional investors in the last quarter, including Inspirion Wealth Advisors LLC, and BlackRock Inc..

How do I buy shares of PDS Biotechnology?

Shares of PDSB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is PDS Biotechnology's stock price today?

One share of PDSB stock can currently be purchased for approximately $2.12.

How big of a company is PDS Biotechnology?

PDS Biotechnology has a market capitalization of $47.20 million. The company earns $-7,000,000.00 in net income (profit) each year or ($3.57) on an earnings per share basis. PDS Biotechnology employs 13 workers across the globe.

What is PDS Biotechnology's official website?

The official website for PDS Biotechnology is www.pdsbiotech.com.

How can I contact PDS Biotechnology?

PDS Biotechnology's mailing address is 25B Vreeland Road, Florham Park NJ, 07932. The company can be reached via phone at 800-208-3343 or via email at [email protected]

This page was last updated on 11/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.